

---

## Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2

**Hørsholm, Denmark, January 20, 2023 – ExpreS<sup>2</sup>ion Biotech Holding AB's affiliate ExpreS<sup>2</sup>ion Biotechnologies ApS ("ExpreS<sup>2</sup>ion") announces that the journal *The Lancet Microbe* published an article about the COVID-19 vaccine candidate ABNCoV2 titled "First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2" co-authored by ExpreS<sup>2</sup>ion scientists.**

Abstract excerpt: "Immunisation with ABNCoV2 was well tolerated, safe, and resulted in a functional immune response. The data support the need for additional clinical development of ABNCoV2 as a second-generation SARS-CoV-2 vaccine. The modular cVLP platform will accelerate vaccine development, beyond SARS-CoV-2."

This publication is a result of the close research collaboration in the COUGH-1 trial study group under the Prevent-nCoV consortium as announced in [August 2021](#) and [November 2021](#).

The scientific article reference: Merel J Smit; Adam F Sander; Maud B P A Ariaans; Cyrielle Fougereux; Constanze Heinzl; Rolf Fendel; Meral Esen; Peter G Kremsner; Rob ter Heine; Heiman F Wertheim; Manja Idorn; Søren Riis Paludan; Alexander P Underwood; Alekxander Binderup; Santseharay Ramirez; Jens Bukh; Max Soegaard; Sayit M Erdogan; Tobias Gustavsson; Stine Clemmensen; Thor G Theander; Ali Salanti; Mette Hamborg; Willem A de Jongh; Matthew B B McCall; Morten A Nielsen; Benjamin G Mordmüller; Robert Dagil; Louise Goksøyr; Thomas M Hulen; Christoph Janitzek; Daniel S Jensen; Sune Justesen; Paul K Khalifé; Andrea Kreidenweiss; Telma Lança; Olivia Lie-Andersen; Karina Teelen; Elena Vidal-Calvo. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. *The Lancet Microbe*. 2023 - [https://doi.org/10.1016/S2666-5247\(22\)00337-8](https://doi.org/10.1016/S2666-5247(22)00337-8). The article can also be found via this [link](#), as well as via the [Research Publications](#) page of ExpreS<sup>2</sup>ion's website.

### Certified Adviser

Svensk Kapitalmarknadsgranskning AB

### For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO

Telephone: +45 4256 6869

E-mail: [buf@expres2ionbio.com](mailto:buf@expres2ionbio.com)

Keith Alexander, CFO

Telephone: +45 5131 8147

E-mail: [ka@expres2ionbio.com](mailto:ka@expres2ionbio.com)

---

### About ExpreS<sup>2</sup>ion

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. ExpreS<sup>2</sup>ion has developed a unique technology platform, ExpreS<sup>2</sup>, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS<sup>2</sup> is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS<sup>2</sup>ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS<sup>2</sup>ion owns 34%. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com).